

| Drug                                                     | Schedule |
|----------------------------------------------------------|----------|
| Aminorex (1585) .....                                    | I        |
| Alpha-ethyltryptamine (7249) .....                       | I        |
| Lysergic acid diethylamide (7315) .....                  | I        |
| Tetrahydrocannabinols (7370) .....                       | I        |
| 4-Bromo-2,5-dimethoxyamphetamine (7391) .....            | I        |
| 4-Bromo-2,5-dimethoxyphenethylamine (7392) .....         | I        |
| 2,5-Dimethoxyamphetamine (7396) .....                    | I        |
| 3,4-Methylenedioxyamphetamine (7400) .....               | I        |
| N-Hydroxy-3,4-methylenedioxyamphetamine (7402) .....     | I        |
| 3,4-Methylenedioxy-N-ethylamphetamine (7404) .....       | I        |
| 3,4-Methylenedioxymethamphetamine (MDMA) (7405) .....    | I        |
| Psilocybin (7437) .....                                  | I        |
| 5-Methoxy-N,N-diisopropyltryptamine (7439) .....         | I        |
| 1-[1-(2-Thienyl)cyclohexyl]piperidine (TCP) (7470) ..... | I        |
| N-Benzylpiperazine (BZP) (7493) .....                    | I        |
| Heroin (9200) .....                                      | I        |
| Normorphine (9313) .....                                 | I        |
| Amphetamine (1100) .....                                 | II       |
| Methamphetamine (1105) .....                             | II       |
| Nabilone (7379) .....                                    | II       |
| 1-Phenylcyclohexylamine (7460) .....                     | II       |
| Phencyclidine (7471) .....                               | II       |
| Cocaine (9041) .....                                     | II       |
| Codeine (9050) .....                                     | II       |
| Ecgonine (9180) .....                                    | II       |
| Levomethorphan (9210) .....                              | II       |
| Levorphanol (9220) .....                                 | II       |
| Meperidine (9230) .....                                  | II       |
| Metazocine (9240) .....                                  | II       |
| Methadone (9250) .....                                   | II       |
| Morphine (9300) .....                                    | II       |
| Thebaine (9333) .....                                    | II       |
| Levo-alphaacetylmethadol (9648) ..                       | II       |
| Remifentanyl (9739) .....                                | II       |
| Carfentanyl (9743) .....                                 | II       |
| Fentanyl (9801) .....                                    | II       |

The company plans to manufacture reference standards.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, **Federal Register** Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than April 22, 2013.

Dated: February 8, 2013.

**Joseph T. Rannazzisi,**  
*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 2013-03893 Filed 2-20-13; 8:45 am]

**BILLING CODE 4410-09-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Manufacturer of Controlled Substances; Notice of Application; GE Healthcare

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on August 31, 2012, GE Healthcare, 3350 North Ridge Avenue, Arlington Heights, Illinois 60004-1412, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Cocaine (9041), a basic class of controlled substance listed in schedule II.

The company plans to manufacture a radioactive product to diagnose Parkinson's disease; and to manufacture a bulk investigational new drug (IND) for clinical trials.

Any other such applicant, and any person who is presently registered with DEA to manufacture such a substance, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than April 22, 2013.

Dated: February 8, 2013.

**Joseph T. Rannazzisi,**  
*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 2013-03895 Filed 2-20-13; 8:45 am]

**BILLING CODE 4410-09-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Manufacturer of Controlled Substances; Notice of Application; Alltech Associates, Inc.

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on November 19, 2012, Alltech Associates Inc., 2051 Waukegan Road, Deerfield, Illinois 60015, made application to the Drug

Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

| Drug                                                                      | Schedule |
|---------------------------------------------------------------------------|----------|
| 5-Methoxy-N,N-dimethyltryptamine (7431) .....                             | I        |
| 2C-E (2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine) (7509) .....             | I        |
| 2C-H (2-(2,5-Dimethoxyphenyl)ethanamine) (7517) .....                     | I        |
| 2C-T-4 (2-(4-isopropylthio)-2,5-dimethoxyphenyl) ethanamine) (7532) ..... | I        |

The company plans to manufacture high purity drug standards used for analytical applications only in clinical, toxicological, and forensic laboratories.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than April 22, 2013.

Dated: February 8, 2013.

**Joseph T. Rannazzisi,**  
*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 2013-03919 Filed 2-20-13; 8:45 am]

**BILLING CODE 4410-09-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Manufacturer of Controlled Substances; Notice of Registration; Cody Laboratories, Inc.

By Notice dated November 1, 2012, and published in the **Federal Register** on November 9, 2012, 77 FR 67398, Cody Laboratories, Inc., ATTN: Richard Asherman, 601 Yellowstone Avenue, Cody, Wyoming 82414, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

| Drug                         | Schedule |
|------------------------------|----------|
| Dihydromorphine (9145) ..... | I        |
| Amphetamine (1100) .....     | II       |
| Methamphetamine (1105) ..... | II       |